key: cord-1014752-unek1dkf
authors: Palleschi, A.; Rosso, L.; Tosi, D.; Righi, I.; Mendogni, P.; Musso, V.; Morlacchi, L.; Vaira, V.; Muscatello, A.; Bandera, A.; Privitera, E.; Scandroglio, A.; De Feo, T.; Cardillo, M.; Grasselli, G.; Pesenti, A.; Ferrero, S.; Gori, A.; Blasi, F.; Zangrillo, A.; Nosotti, M.
title: Lung Transplantation for Acute Respiratory Distress Syndrome Related to COVID-19: The Lesson Learned from the First Two Cases
date: 2021-04-30
journal: The Journal of Heart and Lung Transplantation
DOI: 10.1016/j.healun.2021.01.441
sha: 1ab51b33ddb5a6571678032766c2cd424067021c
doc_id: 1014752
cord_uid: unek1dkf

Purpose The respiratory system, and namely the lung, is undoubtedly the preferential target of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The clinical pictures are extremely various, up to the intensive care unit (ICU) admission for acute respiratory distress syndrome (ARDS). Lung transplantation (LT) is a consolidate therapeutic option for end-stage chronic respiratory diseases. Its role in an acute setting is questionable, particularly due to lack of experiences, donor shortage, and the difficulty to fully evaluate the potential recipient. We report our preliminary experience with the first two cases of LT for SARS-CoV-2 related ARDS, trying to provide some food for thought. Methods We retrospectively analysed our first two cases of bilateral LT for ARDS after COVID-19. We recorded data on pre-transplantation clinical course, transplantation management and outcomes. Results The two patients had a similar clinical evolution of COVID-19. Transplantations were successful in both cases; the first patient is alive and in good condition 5 months after transplantation, while the second died 62 days after surgery. Table 1 shows clinical details and relevant time-points. Conclusion Our experience showed that LT for COVID-19 is feasible. Importantly, observing a dedicated protocol made the procedure safe for the healthcare staff involved. On the other hand, our second unsuccessful case poses relevant questions: first of all, lung transplantation should be reserved to highly selected patient, after careful clinical, infective as well as psychiatric evaluation. The ethical aspects should also be considered in this situation, with regard to the centre rate mortality on waiting list. Anyway, the potential role of LT in the acute and sub-acute/chronic settings suggests the need for maintaining LT centre active during pandemic. Finally, COVID-19, once more, imposes to share clinical experiences.

Methods: 540 LTR from a U.S. center were sent an anonymous, on-line survey comprised of 5 reliable and valid subscales of the COVID Stress Scale (CSS): danger, socio-economics, contamination, checking and traumatic stress. Each subscale included 6 ordinal-scale items for a max subscale score of 24 that when summed yielded a total CSS score up to 120. Higher scores indicate higher stress. Other items included socio-demographics, COVID exposure, testing and impact on seeking medical care. Results: The final sample included 226 LTR (42%) who completed all CSS items, including 58% male, 56% over 60 years, 95% white, 74% married/living with partner. Nearly half reported concerns about face-to-face visits with providers; 42% reported delaying or cancelling medical appointments due to COVID concerns; 26% opted for virtual visits. 96% were never exposed to a known or suspected COVID case. Of the 48% who were tested for COVID, only 2 were positive. The primary sources of information sought about COVID in descending order were transplant providers (29%), TV news (28%), and the internet (15%). Mean total CSS scores were 31.8 (17.8). Mean subscale scores in descending order of distress were danger (9.24), contamination (9.19), checking (6.05), socioeconomic (4.98), and traumatic stress (2.33). LTR with higher total scores were significantly more likely to delay medical appointments (p.004) and cancel face-to-face medical visits (p=.000) due to COVID-related concerns. No significant differences were found due to age, marital status, education, years since transplant, or ever having a COVID test. There were too few minorities to examine differences due to race or ethnicity. Conclusion: COVID-related stress was low. LTRs with higher stress reported worrisome delays or cancelled appointments. Transplant providers are a trusted source of support and information. Purpose: Data on outcomes in lung transplant recipients with SARS-CoV-2 infection remains limited. Given the potential higher COVID-19 severity in lung recipients, the Agence de la biomedecine has limited the transplant program to patients with high-urgency status during the first epidemic wave. The program has been fully restored where possible during the second epidemic wave. This study aimed to assess the impact of COVID-19 on lung recipient mortality in France. Methods: All lung recipients with COVID-19 reported in the French national registry CRISTAL between February 1 st and September 30 th 2020 were included in the study. Patient characteristics were extracted from CRISTAL. Cumulative number of cases by month since February ( Figure  1 ) and case fatality rate (CFR) were calculated. Mortality rates from February to September in the whole 2019 and 2020 recipient cohorts were compared. Survival curves were estimated using Kaplan-Meier method and compared using the log-rank test. Results: Of the 46 patients (median age (IQR) 51 years (39-60), 54% female, median time from transplantation 3.5 years (0.8-7.1)) 88% required hospitalization including 21% in ICU. Eight patients died (CFR: 17.4%). No difference in 3-month survival was observed between 2020 and 2019 recipient cohorts (98.6% 95%CI [98.0%-99.0%] vs 98.4% [97.8%-98.8%], respectively) ( Figure 2) . Conclusion: COVID-19 was associated with lower fatality rate in lung recipients than in other organ transplant recipients and did not result in an excess mortality. These findings suggest that continuing lung transplant activity during the COVID-19 pandemic was a reasonable option. Purpose: The respiratory system, and namely the lung, is undoubtedly the preferential target of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The clinical pictures are extremely various, up to the intensive care unit (ICU) admission for acute respiratory distress syndrome (ARDS). Lung transplantation (LT) is a consolidate therapeutic option for end-stage chronic respiratory diseases. Its role in an acute setting is questionable, particularly due to lack of experiences, donor shortage, and the difficulty to fully evaluate the potential recipient. We report our preliminary experience with the first two cases of LT for SARS-CoV-2 related ARDS, trying to provide some food for thought. Methods: We retrospectively analysed our first two cases of bilateral LT for ARDS after COVID-19. We recorded data on pre-transplantation clinical course, transplantation management and outcomes. Results: The two patients had a similar clinical evolution of COVID-19. Transplantations were successful in both cases; the first patient is alive and in good condition 5 months after transplantation, while the second died 62 days after surgery. Table 1 shows clinical details and relevant timepoints. Conclusion: Our experience showed that LT for COVID-19 is feasible. Importantly, observing a dedicated protocol made the procedure safe for the healthcare staff involved. On the other hand, our second unsuccessful case poses relevant questions: first of all, lung transplantation should be reserved to highly selected patient, after careful clinical, infective as well as psychiatric evaluation. The ethical aspects should also be considered in this situation, with regard to the centre rate mortality on waiting list. Anyway, the potential role of LT in the acute and sub-acute/chronic settings suggests the need for maintaining LT centre active during pandemic. Finally, COVID-19, once more, imposes to share clinical experiences. 

Internal Medicine Department, Respiratory Unit and Adult Cystic Fibrosis Center, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico